A sensitive, accurate and robust Liquid Chromatography Tandem Mass Spectrometry method has been developed and validated to measure voriconazole trough levels in human plasma. The plasma samples were mixed with fluconazole as an Internal Standard and directed to protein precipitation and drug extraction. An aliquot of 1 μl was injected into the chromatographic system and separated by the Acquity BEH C18 column at a flow rate of 0.30 ml/min in a gradient mobile phase consisting of acetonitrile, Ultrapure water (UPW), methanol and formic acid. Voriconazole was detected by a Triple Quadrupole Detector (TQD) operating on Multiple Reaction Monitoring (MRM) and a positive ion mode Electrospray ionization (ESI) Q1 mass: 350.1 m/z, Q3 mass: 281.1 m/z. Method linearity of the calibration curve (0.10 - 8.00 μg/ml) indicated a correlation coefficient r ≥ 0.99. The intra and inter-assay accuracy was within 85% - 115% and the intra and inter-assay precision was ≤5.76%. Voriconazole recovery percentage was between 97.69 - 119.62%. The method was successively applied in routine voriconazole TDM.
References
[1]
Xia, J., Wang, Z., Li, T., Lu, F., Sheng, D. and Huang, W. (2022) Immunosuppressed Patients with Clinically Diagnosed Invasive Fungal Infections: The Fungal Species Distribution, Antifungal Sensitivity and Associated Risk Factors in a Tertiary Hospital of Anhui Province. Infection and Drug Resistance, 15, 321-333. https://doi.org/10.2147/IDR.S351260
[2]
Ravikumar, S., Win, M.S. and Chai, L.Y.A. (2015) Optimizing Outcomes in Immunocompromised Hosts: Understanding the Role of Immunotherapy in Invasive Fungal Diseases. Frontiers in Microbiology, 6, Article 1322. https://doi.org/10.3389/fmicb.2015.01322
[3]
Azoulay, E., Russell, L., Van de Louw, A., et al. (2020) Diagnosis of Severe Respiratory Infections in Immunocompromised Patients. Intensive Care Medicine, 46, 298-314. https://doi.org/10.1007/s00134-019-05906-5
[4]
Kainz, K., Bauer, M.A., Madeo, F. and Carmona-Gutierrez, D. (2020) Fungal Infections in Humans: The Silent Crisis. Microbial Cell, 7, 143-145. https://doi.org/10.15698/mic2020.06.718
[5]
Kauffman, C.A. (1999) Systemic Antifungal Agents. What Is in the Pipeline? Drugs in R & D, 1, 153-159. https://doi.org/10.2165/00126839-199901020-00009
[6]
Zonios, D., Yamazaki, H., Murayama, N., et al. (2014) Voriconazole Metabolism, Toxicity, and the Effect of Cytochrome P450 2C19 Genotype. Journal of Infectious Diseases, 209, 1941-1948. https://doi.org/10.1093/infdis/jiu017
[7]
Aronson, J.K. (2016) Meyler’s Side Effects of Drugs. Elsevier, Amsterdam.
[8]
Sandherr, M. and Maschmeyer, G. (2011) Pharmacology and Metabolism of Voriconazole and Posaconazole in the Treatment of Invasive Aspergillosis—Review of the Literature. European Journal of Medical Research, 16, 139-144. https://doi.org/10.1186/2047-783X-16-4-139
[9]
Alcazar-Fuoli, L. and Mellado, E. (2012) Ergosterol Biosynthesis in Aspergillus fumigatus: Its Relevance as an Antifungal Target and Role in Antifungal Drug Resistance. Frontiers in Microbiology, 3, Article 439. https://doi.org/10.3389/fmicb.2012.00439
[10]
Geist, M.J.P., Egerer, G., Burhenne, J., Riedel, K.-D., Weiss, J. and Mikus, G. (2013) Steady-State Pharmacokinetics and Metabolism of Voriconazole in Patients. Journal of Antimicrobial Chemotherapy, 68, 2592-2599. https://doi.org/10.1093/jac/dkt229
[11]
Yamada, T., Mino, Y., Yagi, T., Naito, T. and Kawakami, J. (2012) Rapid Simultaneous Determination of Voriconazole and Its N-Oxide in Human Plasma Using an Isocratic High-Performance Liquid Chromatography Method and Its Clinical Application. Clinical Biochemistry, 45, 134-138. https://doi.org/10.1016/j.clinbiochem.2011.11.004
[12]
Purkins, L., Wood, N., Ghahramani, P., Greenhalgh, K., Allen, M.J. and Kleinermans, D. (2002) Pharmacokinetics and Safety of Voriconazole Following Intravenous- to Oral-Dose Escalation Regimens. Antimicrobial Agents and Chemotherapy, 46, 2546-2553. https://doi.org/10.1128/AAC.46.8.2546-2553.2002
[13]
Li, Y., Theuretzbacher, U., Clancy, C.J., Nguyen, M.H. and Derendorf, H. (2010) Pharmacokinetic/Pharmacodynamic Profile of Posaconazole. Clinical Pharmacokinetics, 49, 379-396. https://doi.org/10.2165/11319340-000000000-00000
[14]
Lamoureux, F., Duflot, T., Woillard, J.B., et al. (2016) Impact of CYP2C19 Genetic Polymorphisms on Voriconazole Dosing and Exposure in Adult Patients with Invasive Fungal Infections. International Journal of Antimicrobial Agents, 47, 124-131. https://doi.org/10.1016/j.ijantimicag.2015.12.003
[15]
Yi, W.M., Schoeppler, K.E., Jaeger, J., Mueller, S.W., Maclaren, R., Fish, D.N. and Kiser, T.H. (2017) Voriconazole and Posaconazole Therapeutic Drug Monitoring: A Retrospective Study. Annals of Clinical Microbiology and Antimicrobials, 16, Article No. 60. https://doi.org/10.1186/s12941-017-0235-8
Demir, S.Ö., Atici, S., Akkoç, G., et al. (2016) Neurologic Adverse Events Associated with Voriconazole Therapy: Report of Two Pediatric Cases. Case Reports in Infectious Diseases, 2016, Article ID: 3989070. https://doi.org/10.1155/2016/3989070
[18]
Dolton, M.J., Ray, J.E., Chen, S.C.-A., Ng, K., Pont, L.G. and McLachlan, A.J. (2012) Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring. Antimicrobial Agents and Chemotherapy, 56, 4793-4799. https://doi.org/10.1128/AAC.00626-12
[19]
Ashbee, H.R., Barnes, R.A., Johnson, E.M., Richardson, M.D., Gorton, R. and Hope, W.W. (2014) Therapeutic Drug Monitoring (TDM) of Antifungal Agents: Guidelines from the British Society for Medical Mycology. Journal of Antimicrobial Chemotherapy, 69, 1162-1176. https://doi.org/10.1093/jac/dkt508
[20]
Blanco-Dorado, S., Belles Medall, M.D., Pascual-Marmaneu, O., et al. (2021) Therapeutic Drug Monitoring of Voriconazole: Validation of a High Performance Liquid Chromatography Method and Comparison with an ARK Immunoassay. European Journal of Hospital Pharmacy, 28, 154-159. https://doi.org/10.1136/ejhpharm-2019-002155
[21]
Zufía, L., Aldaz, A., Ibáñez, N. and Giráldez, J. (2010) Validation of an LC Method for Therapeutic Drug Monitoring of Voriconazole in Patients. Journal of Bioanalysis and Biomedicine, 2, 35-43. https://doi.org/10.4172/1948-593X.1000019
[22]
Thomas, S.N., French, D., Jannetto, P.J., Rappold, B.A. and Clarke, W.A. (2022) Liquid Chromatography-Tandem Mass Spectrometry for Clinical Diagnostics. Nature Reviews Methods Primers, 2, Article No. 96. https://doi.org/10.1038/s43586-022-00175-x
[23]
Booth, B.P. and Simon, W.C. (2004) Analytical Method Validation. In: Sahajwalla, C., Ed., New Drug Development: Regulatory Paradigms for Clinical Pharmacology and Biopharmaceutics, CRC Press, Boca Raton, 138-158.
[24]
Yousefian, S., Dastan, F., Marjani, M., et al. (2021) Determination of Voriconazole Plasma Concentration by HPLC Technique and Evaluating Its Association with Clinical Outcome and Adverse Effects in Patients with Invasive Aspergillosis. Canadian Journal of Infectious Diseases and Medical Microbiology, 2021, Article ID: 5497427. https://doi.org/10.1155/2021/5497427
[25]
Chawla, P.K., Dherai, A.J. and Ashavaid, T.F. (2016) Plasma Voriconazole Estimation by HPLC. Indian Journal of Clinical Biochemistry, 31, 209-214. https://doi.org/10.1007/s12291-015-0507-z
[26]
ter Avest, M., Veringa, A., van Hateren, K., Koster, R.A., Touw, D.J. and Alffenaar, J.-W. (2018) Method for Therapeutic Drug Monitoring of Voriconazole and Its Primary Metabolite Voriconazole-N-Oxide in Human Serum Using LC-MS/MS. Journal of Applied Bioanalysis, 4, 114-123. https://doi.org/10.17145/jab.18.016
[27]
Prommas, S., Puangpetch, A., Jenjirattithigarn, N., et al. (2017) Development and Validation of Voriconazole Concentration by LC-MS-MS: Applied in Clinical Implementation. Journal of Clinical Laboratory Analysis, 31, e22011. https://doi.org/10.1002/jcla.22011
[28]
Mei, H., Hu, X., Wang, J., Wang, R. and Cai, Y. (2019) Determination of Voriconazole in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry and Its Application in Therapeutic Drug Monitoring in Chinese Patients. Journal of International Medical Research, 48. https://doi.org/10.1177/0300060519887019
